You have 9 free searches left this month | to do more
Showing 1 - 25 of
3,393 items
Trials Per Page
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
M
Active, not recruiting
  • Prolymphocytic Leukemia
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-02-08
Feb 8, 2022
N
Active, not recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +3 more
  • Bronx, New York
  • +3 more
2022-04-05
Apr 5, 2022
M
Active, not recruiting
  • CCND1 Positive
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-01-11
Jan 11, 2022
F
Recruiting
  • Burkitt Lymphoma
  • +2 more
  • Rituximab and Hyaluronidase Human
  • +8 more
  • Kampala, Uganda
    UCI-Fred Hutch Cancer Centre
2022-03-09
Mar 9, 2022
M
Recruiting
  • Ann Arbor Stage III Grade 1 Follicular Lymphoma
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-02-08
Feb 8, 2022
N
Active, not recruiting
  • Ann Arbor Stage III Small Lymphocytic Lymphoma
  • +7 more
  • Washington, District of Columbia
  • +1 more
2022-04-05
Apr 5, 2022
N
Recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +5 more
  • Duarte, California
  • +3 more
2022-04-05
Apr 5, 2022
U
Recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +3 more
  • Laboratory Biomarker Analysis
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2022-02-18
Feb 18, 2022
U
Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • +8 more
  • Ixazomib Citrate
  • +2 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2021-10-20
Oct 20, 2021
M
Active, not recruiting
  • Ann Arbor Stage II Follicular Lymphoma
  • +9 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-02-03
Feb 3, 2022
M
Active, not recruiting
  • Ann Arbor Stage I Grade 1 Follicular Lymphoma
  • +9 more
  • Quality-of-Life Assessment
  • +2 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
2022-02-03
Feb 3, 2022
A
Recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +13 more
  • Polatuzumab Vedotin
  • +3 more
  • Scottsdale, Arizona
  • +9 more
2022-04-07
Apr 7, 2022
U
Terminated
  • Lymphoid Leukemia
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2021-07-20
Jul 20, 2021
O
Not yet recruiting
  • B Acute Lymphoblastic Leukemia
  • Recurrent B Acute Lymphoblastic Leukemia
  • Portland, Oregon
    OHSU Knight Cancer Institute
2021-12-27
Dec 27, 2021
M
Recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • Refractory Diffuse Large B-Cell Lymphoma
  • Chimeric Antigen Receptor T-Cell Therapy
  • +3 more
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
2022-03-08
Mar 8, 2022
N
Active, not recruiting
  • Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma
  • +11 more
  • Washington, District of Columbia
  • +6 more
2022-04-05
Apr 5, 2022
M
Completed
  • Ann Arbor Stage III Grade 1 Follicular Lymphoma
  • +9 more
  • Houston, Texas
    M D Anderson Cancer Center
2021-09-28
Sep 28, 2021
M
Recruiting
  • Aggressive B-Cell Non-Hodgkin Lymphoma
  • +19 more
  • CD47 Antagonist ALX148
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
2021-11-22
Nov 22, 2021
M
Not yet recruiting
  • Mantle Cell Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
2021-02-24
Feb 24, 2021
A
Suspended
  • Steroid-Dependent Nephrotic Syndrome
  • immunoglobulin IV
  • Paris, France
    Robert Debre Hospital
2021-10-01
Oct 1, 2021
N
Active, not recruiting
  • Steroid-Dependent Nephrotic Syndrome
  • Rituximab
  • Mycophenolate Mofetil
  • Kolkata, West Bengal, India
    Nilratan Sircar Medical College and Hospital
2022-04-06
Apr 6, 2022
W
Active, not recruiting
  • Mantle Cell Lymphoma
  • Saint Louis, Missouri
    Washington University School of Medicine
2022-02-02
Feb 2, 2022
L
Recruiting
  • ANCA Associated Vasculitis
  • Rituximab
  • +3 more
  • Leiden, Zuid-Holland, Netherlands
  • +1 more
2021-09-06
Sep 6, 2021
O
Active, not recruiting
  • Central Nervous System Lymphoma
  • Cincinnati, Ohio
  • +3 more
2021-09-15
Sep 15, 2021